CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Vertex launches Phase 3b study of povetacicept autoinjector in IgA nephropathy

By Public Technologies
  • Vertex Pharmaceuticals’ povetacicept met primary and secondary endpoints in Phase 3 RAINIER, reducing proteinuria versus placebo in IgA nephropathy.
  • Results were published in the New England Journal of Medicine and presented at American Society of Nephrology Kidney Week 2026.
  • The interim analysis showed favorable safety with at-home dosing every four weeks.
  • Povetacicept has a November 30 PDUFA target action date.
  • A new Phase 3b PAVANT study is underway to assess patient experience with povetacicept administered by autoinjector in adults with IgA nephropathy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vertex Pharmaceuticals Incorporated published the original content used to generate this news brief via Business Wire (Ref. ID: 20261023342443) on October 23, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk